

# Julie C Martin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8056982/publications.pdf>

Version: 2024-02-01

10  
papers

314  
citations

1307594

7  
h-index

1372567

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

582  
citing authors

#	ARTICLE	IF	CITATIONS
1	KIT Mutations Correlate with Higher Galectin Levels and Brain Metastasis in Breast and Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 2781.	3.7	12
2	Convalescent Plasma: Education and Administration Implications. <i>Clinical Journal of Oncology Nursing</i> , 2021, 25, 28-32.	0.6	1
3	Increased Circulating Levels of Galectin Proteins in Patients with Breast, Colon, and Lung Cancer. <i>Cancers</i> , 2021, 13, 4819.	3.7	18
4	Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19. <i>Respiratory Medicine</i> , 2020, 175, 106188.	2.9	33
5	Genetic Biomarkers: Implications of Increased Understanding and Identification in Lung Cancer Management. <i>Clinical Journal of Oncology Nursing</i> , 2020, 24, 648-656.	0.6	4
6	Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 83, 219-223.	2.0	83
7	Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1635-1643.	2.3	92
8	A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy. <i>Investigational New Drugs</i> , 2012, 30, 1591-1596.	2.6	29
9	Abstract B185: Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor E7016 in combination with temozolomide (TMZ) in patients with advanced solid tumors.. <i>Molecular Cancer Therapeutics</i> , 2011, 10, B185-B185.	4.1	4
10	An Open-Label Clinical Trial Evaluating Safety and Pharmacokinetics of Two Dosing Schedules of Panitumumab in Patients with Solid Tumors. <i>Clinical Colorectal Cancer</i> , 2009, 8, 29-37.	2.3	38